Three-dimensional patient-derived endometriosis model for drug evaluation.
Endometriomsis (EMs) is a complex and chronic gynecological disease characterized by distressing symptoms. Its pathogenesis remains unknown, and there is no effective treatment. Therefore, establishing patient-derived models is crucial for …
The inhibition of deep peritoneal endometriosis by Andrographolide through macrophage M1 activity in an endometriosis mice model.
This study aims to demonstrate that Andrographolide, an herbal immunostimulant, can influence M1 macrophages to inhibit inflammation, including the growth of endometriosis caused by inflammation. This study evaluates the effects …
Differences in response to dienogest therapy among different phenotypes of endometriosis: A single-center retrospective cohort analysis.
This study aims to investigate the differences in response to dienogest (DNG) therapy among patients with 3 different phenotypes of endometriosis: ovarian endometrioma (OMA), superficial peritoneal endometriosis (SUP), and deep …
Dydrogesterone and Letrozole Combination for the Treatment of Endometriosis: A Mechanism-Based Therapeutic Approach.
Endometriosis is a complex, estrogen-dependent disease with limited effective treatments that often focus on symptom management rather than addressing the underlying pathology. Current therapies, such as progestins and GnRH agonists, …
Barriers affecting medication adherence to dienogest among patients with ovarian endometriosis: a qualitative study.
To explore barriers affecting medication adherence (e.g., missed doses, forgotten doses, or discontinuation) among patients with Ovarian Endometriosis (OE) using the Capability, Opportunity, Motivation - Behaviour (COM-B) behavioural change model …
Efficacy and acceptability of dienogest among patients with endometriosis in Thailand.
Endometriosis is a chronic condition affecting women of reproductive age and often associated with pain, impaired fertility, and reduced quality of life. Management requires long-term strategies, with medical treatment preferred …
Expression of concern: "Is dienogest a convenient treatment option for cesarean scar endometriosis or should it be treated surgically?". [Eur. J. Obstet. Gynecol. Reprod. Biol. 282 (2023) 110-115].
Correction to: Efficacy and Safety of 48-Week Low-Dose Dienogest Treatment in Patients with Endometriosis-Associated Dysmenorrhea: A Randomized, Open-Label, Parallel-Group Trial.